Peptidomimetic inhibitors targeting TrkB/PSD-95 signaling improves cognition and seizure outcomes in an Angelman Syndrome mouse model
Angelman syndrome (AS) is a rare genetic neurodevelopmental disorder with profoundly
debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic …
debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic …
Peptidomimetic inhibitors targeting TrkB/PSD-95 signaling improves cognition and seizure outcomes in an Angelman Syndrome mouse model
EZ Huie, X Yang, MS Rioult-Pedotti… - … : the preprint server …, 2024 - pubmed.ncbi.nlm.nih.gov
Angelman syndrome (AS) is a rare genetic neurodevelopmental disorder with profoundly
debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic …
debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic …
Peptidomimetic inhibitors targeting TrkB/PSD-95 signaling improves cognition and seizure outcomes in an Angelman Syndrome mouse model
EZ Huie, X Yang, MS Rioult-Pedotti, M Naik, YA Huang… - 2024 - europepmc.org
Angelman syndrome (AS) is a rare genetic neurodevelopmental disorder with profoundly
debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic …
debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic …
Peptidomimetic inhibitors targeting TrkB/PSD-95 signaling improves cognition and seizure outcomes in an Angelman Syndrome mouse model
EZ Huie, X Yang, MS Rioult-Pedotti, M Naik… - bioRxiv - ncbi.nlm.nih.gov
Angelman syndrome (AS) is a rare genetic neurodevelopmental disorder with profoundly
debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic …
debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic …